LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Отворен

38.79 -1.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

38.16

Максимум

39.33

Ключови измерители
By Trading Economics
Приходи	-7.4M -81M
EPS	-0.5
Марж на печалбата	-1,582.642
Служители	205
EBITDA	-6.8M -79M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+8.53% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.9B 6.1B
Предишно отваряне	40.11
Предишно затваряне	38.79

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.12.2025 г., 20:41 ч. UTC

Печалби

Значими двигатели на пазара

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4.12.2025 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4.12.2025 г., 17:43 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4.12.2025 г., 17:01 ч. UTC

Печалби

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Scales Hits Mark With Earnings Guidance -- Market Talk

4.12.2025 г., 21:37 ч. UTC

Печалби

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4.12.2025 г., 21:36 ч. UTC

Печалби

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4.12.2025 г., 20:04 ч. UTC

Пазарно говорене

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4.12.2025 г., 19:54 ч. UTC

Пазарно говорене

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4.12.2025 г., 19:33 ч. UTC

Пазарно говорене

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4.12.2025 г., 18:58 ч. UTC

Пазарно говорене

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4.12.2025 г., 16:33 ч. UTC

Пазарно говорене

Печалби

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

8.53% нагоре

12-месечна прогноза

Среден 42.5 USD 8.53%

Висок 65 USD

Нисък 20 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.